Deriving Human Intestinal Organoids with Functional Tissue-Resident Macrophages All From Pluripotent Stem Cells
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Dec 2024 · 1 min read
In brief
In brief
Researchers developed human intestinal organoids containing functional tissue-resident macrophages by co-culturing separately differentiated cell types from pluripotent stem cells. The macrophages persisted for weeks, exhibited fetal intestine-like transcriptional profiles, and demonstrated phagocytic and inflammatory responses, creating a more physiologically complete disease modeling platform.
Written by the GCMD Library team from the article.
Statements in this article
Most published human organoid model systems lack resident immune cells, limiting their potential as disease avatars.
Human intestinal organoids derived from pluripotent stem cells contain epithelial and various mesenchymal cell types but lack immune cells.
Human intestinal organoids and macrophages are generated separately through directed differentiation of human pluripotent stem cells and combined in vitro.
Following 2 weeks of coculture, organoids can be used for transcriptional profiling, functional analysis of macrophages, or transplanted into immunocompromised mice and matured in vivo for an additional 10-12 weeks.
Macrophages incorporated into developing human intestinal organoids persist for 2 weeks in vitro and for at least 12 weeks in vivo.
Cocultured macrophages have a transcriptional signature that resembles those in the human fetal intestine, indicating acquisition of tissue-resident macrophage features.
Human intestinal organoid macrophages can phagocytose bacteria and produce inflammatory cytokines in response to proinflammatory signals such as lipopolysaccharide.
Inflammatory cytokine production by human intestinal organoid macrophages in response to lipopolysaccharide can be reversed with interleukin-10.
